Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression

Gruden, Marina A., Sewell, Robert David Edmund, Yanamandra, Kiran, Davidova, Tatyana V., Kucheryanu, Valery G., Bocharov, Evgeny V., Bocharova, Olga A., Polyschuk, Vsevolod V., Sherstnev, Vladimir V. and Morozova-Roche, Ludmilla A. 2011. Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. Journal of Neuroimmunology 233 (1-2) , pp. 221-227. 10.1016/j.jneuroim.2010.12.001

Full text not available from this repository.

Abstract

The aim was to ascertain any possible linkage between humoral immune responses to principal biomarkers (α-synuclein monomers, its toxic oligomers or fibrils, dopamine and S100B) and cellular immunity in Parkinson's disease development. There were elevated autoantibody titers to α-synuclein monomers, oligomers plus fibrils in 72%, 56%, and 17% of Parkinsonian patients respectively with a 5-year disease duration. Additionally, there were increased titers to dopamine and S100B (96% and 89%) in the 5-year patient group. All of these values subsided in 10-year sufferers. Furthermore, CD3+, CD4+, CD8+ T-lymphocyte and B-lymphocyte subsets declined in the patient cohort during Parkinsonism indicating disease associated reductions in these lymphocyte subsets.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RS Pharmacy and materia medica
Uncontrolled Keywords:	Parkinson's disease; α-synuclein; amyloid toxicity; autoantibodies; T-cells; B-cells.
Publisher:	Elsevier
ISSN:	0165-5728
Last Modified:	04 Jun 2017 06:30
URI:	https://orca.cardiff.ac.uk/id/eprint/61042

Citation Data

Cited 47 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item